SOC: Phosphodiesterase type 5 (PDE-5) inhibitor clinical trials

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

This study is testing if a medicine called selexipag can help children aged 2-17 with a serious lung condition called pulmonary hypertension. It aims to see if adding selexipag to their usual treatment can slow down the disease compared to a dummy medicine.